FDA Clears Roxicet for Generic Copies, No Safety Snags
Published Date: 8/4/2025
Notice
Summary
The FDA says ROXICET tablets (5 mg oxycodone and 325 mg acetaminophen) weren’t pulled from the market because of safety or effectiveness problems. This means drug companies can now apply to sell generic versions, as long as they follow the rules. Patients and pharmacies could see more affordable options soon, with no safety worries slowing things down.
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
Generic Approval Pathway Opens
The FDA determined that ROXICET (oxycodone hydrochloride and acetaminophen) tablet, 5 mg/325 mg, was not withdrawn for reasons of safety or effectiveness. Because of this, the FDA can approve abbreviated new drug applications (ANDAs) for the 5 mg/325 mg tablet if all other legal and regulatory requirements are met.
Patients and Pharmacies May See Cheaper Options
Because FDA can now approve ANDAs for the oxycodone HCl and acetaminophen 5 mg/325 mg tablet, patients who use that medicine and pharmacies could see more affordable generic options become available. The approval pathway is allowed only if all other legal and regulatory requirements are met.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11739 — Medical Devices; Immunology and Microbiology Devices; Classification of the Simple Point-of-Care Device to Directly Detect SARS-CoV-2 Viral Targets From Clinical Specimens in Near-Patient Settings
The FDA is officially putting simple COVID-19 rapid test devices into a safer, easier-to-manage category called Class II. This change means these tests can get to patients faster and with fewer hoops to jump through, while still making sure they work well and stay safe. Starting June 11, 2026, companies making these tests will follow new rules that help speed up innovation without extra costs.
2026-11740 — Medical Devices; Immunology and Microbiology Devices; Classification of the Spinal Muscular Atrophy Newborn Screening Test System
The FDA is officially putting the Spinal Muscular Atrophy (SMA) newborn screening test into class II, meaning it has special safety rules but fewer hurdles than the strictest category. This change helps make the test safer and easier to get to babies who need it, starting June 11, 2026, with the classification effective since November 2022. Labs and device makers will benefit from clearer rules and faster access, helping catch SMA early without extra costs or delays.
2026-11760 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Establishment, Maintenance, and Availability of Records; Additional Traceability Records for Certain Foods
The FDA is asking for approval to collect extra records from food businesses that handle certain high-risk foods. This helps track food sources quickly to keep everyone safe. Food companies should get ready to keep and share these new records, and comments on this plan are due by July 13, 2026.
2026-11762 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Procedures for the Safe Processing and Importing of Fish and Fishery Products
The FDA is asking for approval to keep collecting info from seafood processors and importers to make sure fish products are safe using a system called HACCP. This affects anyone who processes or imports fish and requires them to keep records showing they’re following safety rules. Comments on this plan are open until July 13, 2026, and there’s no new cost, just a continuation of current paperwork.
2026-11589 — Medical Devices; Ear, Nose, and Throat Devices; Classification of the Combined Acoustic and Electrical External Stimulation Device for the Relief of Tinnitus
The FDA has officially placed the combined acoustic and electrical external stimulation device for tinnitus relief into class II, meaning it now has special safety rules but fewer regulatory hurdles. This change helps patients get access to this innovative device faster and ensures it’s safe and effective. The new classification is effective June 10, 2026, with the rules applying retroactively from March 6, 2023.
2026-11578 — Amending Over-the-Counter Monograph M020: Sunscreen Drug Products for Over-the-Counter Human Use, and Related Information
The FDA just gave a thumbs-up to adding bemotrizinol as a new active ingredient in sunscreens, letting it be used up to 6% concentration. This means sunscreen makers can now include this ingredient, which is safe and effective, in their products. The change is official as of June 10, 2026, and could lead to better sun protection options without extra costs for consumers.
Previous / Next Documents
Previous: 2025-14706 — Agency Information Collection Activities; Proposed eCollection eComments Requested; New Collection; Title-DEA Voluntary Wellness Program Healthcare Provider Clearance
The Drug Enforcement Administration (DEA) wants to start a new voluntary wellness program for healthcare providers. They’re asking for feedback on a new form to help make this happen, aiming to support healthcare workers’ well-being without adding extra costs or big time commitments. If you’re a healthcare provider, this is your chance to weigh in before the plan moves forward!
Next: 2025-14708 — Unwrought Palladium From Russia; Institution of Antidumping and Countervailing Duty Investigations and Scheduling of Preliminary Phase Investigations
The U.S. is launching investigations to see if cheap or government-supported palladium from Russia is hurting American businesses. If the claims are true, extra taxes might be added to these imports to protect U.S. companies. The first big decision is expected by September 15, 2025, so things are moving fast!